Profile data is unavailable for this security.
About the company
Comera Life Sciences Holdings, Inc. is a pre-clinical biotechnology company. The Company applies a knowledge of formulation science and technology to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The Company is engaged in developing an internal portfolio of therapeutic product candidates using its proprietary formulation platform, SQore. Its proprietary formulation platform, SQore, is designed to transform biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. Its product programs include CLS-001, a preclinical stage bio better for Crohn’s and Ulcerative Colitis disease, and CLS-002, a preclinical stage bio better for various oncology indications. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to its partners’ biologic medicines to deliver enhanced SQ formulations.
- Revenue in USD (TTM)1.00m
- Net income in USD-9.35m
- Incorporated2022
- Employees12.00
- LocationComera Life Sciences Holdings Inc12 Gill Street, Suite 4650WOBURN 01801United StatesUSA
- Phone+1 (617) 871-2101
- Fax+1 (561) 694-1639
- Websitehttps://www.comeralifesciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Pharmacology (USA) Ltd | 0.00 | -105.18k | 599.73k | 0.00 | -- | -- | -- | -- | -0.0009 | -0.0009 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -976.60 | -1,219.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.29 | -- | -- | -- |
Capstone Therapeutics Corp | 0.00 | -358.00k | 646.20k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
Pharmagreen Biotech Inc | 1.56k | -500.66k | 663.65k | 0.00 | -- | -- | -- | 425.41 | -0.0011 | -0.0011 | 0.00 | -0.0045 | 0.0094 | -- | 3.35 | -- | -302.10 | -472.20 | -- | -- | 11.54 | -- | -32,096.15 | -- | 0.0194 | -71.71 | -- | -- | -- | -- | 80.68 | -- | -- | -- |
Bluejay Diagnostics Inc | 0.00 | -9.74m | 672.69k | 10.00 | -- | 0.0595 | -- | -- | -61.41 | -61.41 | 0.00 | 10.02 | 0.00 | -- | -- | 0.00 | -122.06 | -- | -149.68 | -- | -- | -- | -- | -- | -- | -- | 0.0048 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
Better Therapeutics Inc | 0.00 | -31.57m | 718.01k | 54.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | -0.2449 | 0.00 | -- | -- | 0.00 | -162.15 | -- | -378.28 | -- | -- | -- | -- | -- | -- | -15.18 | 3.27 | -- | -- | -- | 1.43 | -- | -- | -- |
Respirerx Pharmaceuticals Inc | 0.00 | -2.17m | 803.92k | 2.00 | -- | -- | -- | -- | -0.014 | -0.014 | 0.00 | -0.0412 | 0.00 | -- | -- | 0.00 | -2,255.78 | -2,491.69 | -- | -- | -- | -- | -- | -- | -- | -2.90 | -- | -- | -- | -- | -12.78 | -- | -- | -- |
Comera Life Sciences Holdings Inc | 1.00m | -9.35m | 822.24k | 12.00 | -- | -- | -- | 0.8219 | -0.4901 | -0.4901 | 0.0512 | 0.0033 | 0.2498 | -- | 5.08 | 83,367.50 | -224.98 | -- | -1,094.30 | -- | 73.52 | -- | -900.55 | -- | -- | -- | 0.00 | -- | 97.95 | -- | -237.10 | -- | -- | -- |
GlobeStar Therapeutics Corp | 0.00 | -1.98m | 872.19k | -- | -- | -- | -- | -- | -0.0023 | -0.0023 | 0.00 | -0.0015 | 0.00 | -- | -- | -- | -38,103.72 | -4,657.88 | -- | -- | -- | -7,790.20 | -- | -2,834,410.00 | -- | -21.00 | -- | -- | -- | -- | -31.01 | -- | -- | -- |
International Stem Cell Corp | 7.83m | -327.00k | 907.70k | 29.00 | -- | -- | -- | 0.1159 | -0.0409 | -0.0409 | 0.9785 | 0.0045 | 1.46 | 2.53 | 11.87 | 270,069.00 | -5.81 | -29.22 | -68.13 | -73.82 | 58.58 | 59.49 | -3.97 | -21.01 | 0.4672 | -6.06 | 0.9898 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
GRI Bio Inc | 0.00 | -12.77m | 947.93k | 4.00 | -- | 0.138 | -- | -- | -349.68 | -349.68 | 0.00 | 11.38 | 0.00 | -- | -- | 0.00 | -382.23 | -192.93 | -869.57 | -353.99 | -- | -- | -- | -37,650.49 | -- | -16.80 | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |